Efficacy of local nasal immunotherapy for Dp2-induced airway inflammation in mice: Using Dp2 peptide and fungal immunomodulatory peptide

Liu, Yi-Hsia; Kao, Mei-Chen; Lai, Yih‐Loong; Tsai, Jaw‐Ji

doi:10.1067/mai.2003.1619

Cited by 45 publications

(47 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is a noncovalently linked homodimer, and it is the first fibronectin III domain containing protein of fungal origin [23]. We have previously demonstrated that LNIT with FIP targeting the Der p 2 peptide and mixtures of both were able to inhibit Der p 2-induced airway inflammation [24]. In this study, we hypothesized that LNIT with a mixture of Der p 2 and FIP would not only downregulate Der p 2-induced airway inflammation, but would also cause suppression of Der p-induced airway inflammation through increased concentrations of secretory IgA in the airways.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Production of Salivary Immunoglobulin A and Suppression of <i>Dermatophagoides pteronyssinus</i>-Induced Airway Inflammation by Local Nasal Immunotherapy

Liu¹,

Tsai²

2005

Int Arch Allergy Immunol

Self Cite

View full text Add to dashboard Cite

Background: Local nasal immunotherapy (LNIT) is an effective immunotherapeutic modality, especially when targeting a single immunodominant peptide from an allergen. However, the working mechanisms of LNIT are poorly understood. We hypothesized that LNIT with a mixture of group 2 allergens of Dermatophagoides pteronyssinus (Der p 2) protein and fungal immunomodulatory peptide (FIP) would generate suppression of Der p-induced airway inflammation through immunoglobulin (Ig) A secretion in the airways. Method: Mice were sensitized with recombinant Der p 2 (rDer p 2) and Der p followed by LNIT with rDer p 2 in conjunction with FIP. After intratracheal challenge with rDer p 2 and Der p, the airway inflammation was determined by analyzing the cell subpopulation and cytokine concentration in the bronchoalveolar lavage fluid. The allergen-specific IgE, IgG2a and IgG in the sera and IgA in the saliva were measured by ELISA. Results: LNIT with rDer p 2 in conjunction with FIP could downregulate the lymphocyte infiltration in both rDer p 2- and Der p-induced airway inflammation. Both total and specific IgA in the saliva were increased after LNIT. Serum levels of IL-4, IL-10 and specific IgE were reduced and the specific IgG2a and IgG increased after LNIT. After LNIT, there was a reduction of airway hypersensitivity at 30 min after allergen challenge in the rDer p 2-and Der p-sensitized mice, with a significant decrease only in rDer p 2-sensitized mice. Conclusion: LNIT with rDer p 2 in conjunction with FIP was not only able to suppress rDer p 2-induced airway inflammation but also generate suppression of Der p-induced airway inflammation. The simultaneous reduction of IL-4 and IL-10 indicated that IL-10-producing cells were not activated by LNIT. The increment of IgA in the airway might play a role in the prevention of airway inflammation.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Groups of 4 mice had received bronchoalveolar lavage, and the fluid (BALF) was collected as previously described [24]. One separate dose of 1 ml of sterile endotoxin-free saline was injected into the lungs via the trachea of each mouse.…”

Section: Introductionmentioning

confidence: 99%

Production of Salivary Immunoglobulin A and Suppression of <i>Dermatophagoides pteronyssinus</i>-Induced Airway Inflammation by Local Nasal Immunotherapy

Liu¹,

Tsai²

2005

Int Arch Allergy Immunol

Self Cite

View full text Add to dashboard Cite

show abstract

“…After LNIT with Der p2 peptides (Der p2 28-40 and Der p2 28-40A) and FIP-fve, mixtures of both were able to inhibit Der p-induced airway hyper-responsiveness and inflammation. 34) Moreover, LNIT with recombinant Der p 2 (rDer p 2) in conjunction with FIP-fve was able to suppress rDer p 2-induced and even Der pinduced airway inflammation. has not been resolved; this will be determined based on the next generation sequencing technology in our future work.…”

Section: Discussionmentioning

confidence: 99%

Alleviation of Dermatophagoides microceras-induced allergy by an immunomodulatory protein, FIP-fve, from Flammulina velutipes in mice

Chang

Hsiao

Hung

et al. 2015

Bioscience, Biotechnology, and Biochemistry

View full text Add to dashboard Cite

“…La inmunización de conejos con estos péptidos produjo anticuerpos IgG que mostraron, en ensayos in vitro, capacidad de inhibir la degranulación de basófilos de pacientes alérgicos a Phl p 7 (32). En un modelo animal de alergia por ácaros (40), se demostró que la administración nasal de péptidos de Der f 2 que contenían epítopos T unidos a una secuencia fúngica inmunoestimuladora (FPI-fve) alivió los síntomas de hipersensibilidad inmediata. En ensayos in vitro se demostró que estas preparaciones indujeron proliferación de células Treg secretoras de IL-10 y TGF-β con capacidad de bloquear la proliferación de células mononucleares de sangre periférica, lo cual sugiere que de administrarse a pacientes alérgicos aumentarían las Treg capaces de contrarrestar el efecto de células proinflamatorias y mejorarían la sintomatología alérgica.…”

Section: Inmunoterapia Con Péptidosunclassified

Nuevos esquemas de inmunoterapia específicas con alérgenos

Cantillo¹,

Puerta²

2010

biomedica

View full text Add to dashboard Cite

Las enfermedades alérgicas, como el asma y la rinitis, son un problema de salud de importancia en todos los países y con una tendencia global al aumento en su prevalencia. La inmunoterapia específica con extractos alergénicos naturales es el único tratamiento con antígenos dirigido a brindar una protección duradera y que beneficia a la mayoría de la población tratada. Sin embargo, este tratamiento presenta inconvenientes porque los extractos son preparaciones de difícil estandarización y gran complejidad en sus componentes, lo que aumenta los riesgos de que se presenten reacciones adversas y nuevas sensibilizaciones a otros antígenos presentes en el extracto. Por lo tanto, se ha planteado la necesidad de desarrollar nuevos esquemas de inmunoterapia específica con el alérgeno en los que se utilicen moléculas bien caracterizadas de fácil estandarización y manejo, con las que se puedan brindar tratamientos más seguros y eficaces. Con estos nuevos esquemas se han diseñado vacunas basadas en alérgenos recombinantes y variantes o péptidos derivados de éstos, para ser administrados solos o con adyuvantes en preparaciones que favorecen la captación y presentación antigénica por las células dendríticas o tienen como blanco las células efectoras, como mastocitos y basófilos. Los estudios in vitro, en modelos animales y algunos en fase clínica en humanos, indican que estas preparaciones pueden brindar protección frente a la exposición alergénica o mejorar la sintomatología, al inducir la producción de anticuerpos bloqueadores de la actividad de la IgE, de células T reguladoras y de citocinas del perfil Th1.Palabras claves: alergia e inmunología, inmunoterapia, alérgenos, desensibilización, inmunoglobulina E, factores inmunológicos. New approaches for allergen-specific immunotherapyRates of allergic diseases such as asthma and rhinitis are on the rise as important health problems in every country of the world. Allergen specific immunotherapy with natural allergenic extracts is a treatment directed to changing the natural course of these diseases, and is a treatment that has reported beneficial effects in a majority of allergic patients. However, this treatment is difficult because of the complex composition of the extracts. The composition is difficult to standardize and, consequently, the risk of anaphylactic shock is increased; furthermore, sensitization can occur to other antigens present in the extract. Therefore, new allergen specific immunotherapy approaches are needed. Chemically defined and standardized antigens are more easily managed and provide a safer and more efficient treatment. Vaccines for immunotherapy have already been designed, based on recombinant allergens, variants (or peptides derived from them), that can be administrated alone or in combination with adjutants. Some of these preparations are indicated for facilitating the uptake and antigenic presentation by dendritic cells, or by targeting the mast cells and basophiles. Studies in vitro, in animal models and clinical trials in allergic patients, indi...

show abstract

Efficacy of local nasal immunotherapy for Dp2-induced airway inflammation in mice: Using Dp2 peptide and fungal immunomodulatory peptide

Cited by 45 publications

References 40 publications

Production of Salivary Immunoglobulin A and Suppression of <i>Dermatophagoides pteronyssinus</i>-Induced Airway Inflammation by Local Nasal Immunotherapy

Production of Salivary Immunoglobulin A and Suppression of <i>Dermatophagoides pteronyssinus</i>-Induced Airway Inflammation by Local Nasal Immunotherapy

Alleviation of Dermatophagoides microceras-induced allergy by an immunomodulatory protein, FIP-fve, from Flammulina velutipes in mice

Nuevos esquemas de inmunoterapia específicas con alérgenos

Contact Info

Product

Resources

About